Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic Marketplace
Five-year arrangement with
Distributors representing several orthopedic manufacturers with
exclusive territory designations participated in a pilot program, which
began in
“The ability to provide patients with up to 72 hours of non-opioid
postsurgical pain control without the need for catheters or external
devices—which can limit mobility and delay the ambulation that we know
is critical to the rehabilitation process following orthopedic
procedures—makes EXPAREL an important option for patient care,” said
Under the terms of the agreement, CrossLink is compensated on a variable
cost basis, based on performance in designated hospitals and geography,
reported monthly to Pacira. The parties may elect, by mutual agreement,
to add additional orthopedic distributors and/or geographies to the
five-year agreement. In addition, Pacira and Crosslink have mutual
termination rights under the agreement, with Pacira having unilateral
termination rights under certain circumstances. The agreement also
permits Pacira to terminate without cause effective
To further support this interest in EXPAREL among orthopedic surgeons,
About Pacira
About CrossLink
About EXPAREL®
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours. Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures and additional studies are underway to further demonstrate the safety and efficacy in other procedures. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about our plans and
expectations regarding EXPAREL, and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” and similar
expressions, constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including risks
relating to: the success of our sales efforts in support of the
commercialization of EXPAREL; the rate and degree of market acceptance
of EXPAREL; the size and growth of the potential markets for EXPAREL and
our ability to serve those markets; our plans to expand the indications
of EXPAREL to include nerve block, including the timing and success of
an sNDA; our plans to continue to manufacture and provide support
services for our commercial partners who have licensed DepoCyt(e); our
commercialization and marketing capabilities; and other factors
discussed in the “Risk Factors” of our most recent Annual Report on Form
10-K for the fiscal year ended
Source:
Pacira Pharmaceuticals, Inc.
Company Contact:
Jessica Cho,
973-254-3574
or
Pure Communications, Inc.
Media Contact:
Susan
Heins, 864-286-9597
sjheins@purecommunicationsinc.com